These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31518438)

  • 1. BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers.
    Lavitrano M; Ianzano L; Bonomo S; Cialdella A; Cerrito MG; Pisano F; Missaglia C; Giovannoni R; Romano G; McLean CM; Voest EE; D'Amato F; Noli B; Ferri GL; Agostini M; Pucciarelli S; Helin K; Leone BE; Canzonieri V; Grassilli E
    J Pathol; 2020 Feb; 250(2):134-147. PubMed ID: 31518438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors.
    Grassilli E; Cerrito MG; Bonomo S; Giovannoni R; Conconi D; Lavitrano M
    Front Cell Dev Biol; 2021; 9():690365. PubMed ID: 34164404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of GSK3B bypass drug resistance of p53-null colon carcinomas by enabling necroptosis in response to chemotherapy.
    Grassilli E; Narloch R; Federzoni E; Ianzano L; Pisano F; Giovannoni R; Romano G; Masiero L; Leone BE; Bonin S; Donada M; Stanta G; Helin K; Lavitrano M
    Clin Cancer Res; 2013 Jul; 19(14):3820-31. PubMed ID: 23729362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer.
    Morishita A; Gong J; Nomura T; Yoshida H; Izuishi K; Suzuki Y; Kushida Y; Haba R; D'Armiento J; Masaki T
    Int J Oncol; 2010 Oct; 37(4):829-35. PubMed ID: 20811704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation.
    Grassilli E; Pisano F; Cialdella A; Bonomo S; Missaglia C; Cerrito MG; Masiero L; Ianzano L; Giordano F; Cicirelli V; Narloch R; D'Amato F; Noli B; Ferri GL; Leone BE; Stanta G; Bonin S; Helin K; Giovannoni R; Lavitrano M
    Oncogene; 2016 Aug; 35(33):4368-78. PubMed ID: 26804170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer.
    Tankiewicz-Kwedlo A; Hermanowicz JM; Domaniewski T; Pawlak K; Rusak M; Pryczynicz A; Surazynski A; Kaminski T; Kazberuk A; Pawlak D
    Br J Pharmacol; 2018 Mar; 175(5):743-762. PubMed ID: 29160911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer.
    Gao S; Soares F; Wang S; Wong CC; Chen H; Yang Z; Liu W; Go MYY; Ahmed M; Zeng Y; O'Brien CA; Sung JJY; He HH; Yu J
    Oncogene; 2021 Dec; 40(48):6601-6613. PubMed ID: 34621019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer.
    Lee JH; Lee SW
    Mol Biol Rep; 2019 Aug; 46(4):3835-3842. PubMed ID: 31028570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
    Liu L; Qiu S; Liu Y; Liu Z; Zheng Y; Su X; Chen B; Chen H
    Neoplasma; 2016; 63(2):193-200. PubMed ID: 26774139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer.
    Song H; Zeng J; Roychoudhury S; Biswas P; Mohapatra B; Ray S; Dowlatshahi K; Wang J; Band V; Talmon G; Bhakat KK
    Mol Cancer Ther; 2020 Jan; 19(1):258-269. PubMed ID: 31575655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy.
    Martino-Echarri E; Henderson BR; Brocardo MG
    Oncotarget; 2014 Oct; 5(20):9889-900. PubMed ID: 25301724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB.
    Oliver Metzig M; Fuchs D; Tagscherer KE; Gröne HJ; Schirmacher P; Roth W
    Oncogene; 2016 Jun; 35(26):3399-409. PubMed ID: 26522725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
    Pan Y; Chiu YH; Chiu SC; Cho DY; Lee LM; Wen YC; Whang-Peng J; Hsiao CH; Shih PH
    Anticancer Res; 2020 Nov; 40(11):6093-6099. PubMed ID: 33109547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
    Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
    Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.
    Sala L; Cirillo G; Riva G; Romano G; Giussani C; Cialdella A; Todisco A; Virtuoso A; Cerrito MG; Bentivegna A; Grassilli E; Ardizzoia A; Bonoldi E; Giovannoni R; Papa M; Lavitrano M
    Front Mol Neurosci; 2019; 12():2. PubMed ID: 30733667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits.
    Denise C; Paoli P; Calvani M; Taddei ML; Giannoni E; Kopetz S; Kazmi SM; Pia MM; Pettazzoni P; Sacco E; Caselli A; Vanoni M; Landriscina M; Cirri P; Chiarugi P
    Oncotarget; 2015 Dec; 6(39):41706-21. PubMed ID: 26527315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways.
    Gao Y; Xiao X; Zhang C; Yu W; Guo W; Zhang Z; Li Z; Feng X; Hao J; Zhang K; Xiao B; Chen M; Huang W; Xiong S; Wu X; Deng W
    J Pineal Res; 2017 Mar; 62(2):. PubMed ID: 27865009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of PRDX2 sensitizes colon cancer cells to 5-FU by suppressing the PI3K/AKT signaling pathway.
    Xu J; Zhang S; Wang R; Wu X; Zeng L; Fu Z
    Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28432271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.